Key Highlights
- Ingredion is paying 595 pence per share in cash, with permitted dividends taking total value to 615 pence.
- At the Court Meeting on 28 July 2026, 98.64% of votes cast by value were in favour.
- The 595 pence cash price is a 58.7% premium to the undisturbed close of around 375 pence.
- Completion is expected in the second half of 2027, subject to antitrust conditions and court sanction.
Tate & Lyle PLC (LSE:TATE) has spent the summer of 2026 as one of the most-watched stocks on the London Stock Exchange while offering little left for new investors to discover. On 8 June 2026 the FTSE 250 food and beverage ingredients group agreed an all-cash takeover, backed by its board, by NYSE-listed Ingredion Incorporated at 595 pence per share, plus up to 20 pence of permitted dividends, valuing the company at about £2.7bn. Shareholders approved the deal on 28 July with more than 98% support.
That leaves a narrower question for anyone holding or considering the shares. With completion not expected until the second half of 2027 and demanding antitrust conditions still to clear, is the gap between today's price and the 615 pence total value a source of return, or a warning about deal risk?
Ingredion's £2.7bn agreed cash offer
The 8 June 2026 Rule 2.7 announcement set out cash consideration of 595 pence per share. Shareholders also keep the 13.2 pence FY26 final Dividend and an Interim Dividend of up to 6.8 pence, taking the total value to 615 pence. On the cash element alone, the value of the shares is £2.7bn ($3.6bn) and the Enterprise value £3.7bn ($5.0bn), roughly 9.1 times adjusted EBITDA for the twelve months to 31 March 2026.
The 595 pence cash price is a 58.7% premium to the closing price on 13 May 2026, the day before Ingredion's approach became public, implying an undisturbed price of around 375 pence; the 615 pence total value is 64.0% above that close. Ingredion's opening proposal of 530 pence, 80% cash and 20% stock, was rejected as undervaluing the company, and four further proposals followed before the all-cash deal was agreed.
Chairman David Hearn said the board unanimously backed the offer as "an attractive opportunity for shareholders to crystallise value in cash," weighing that certainty against the execution risks of the company's own transformation in a difficult macroeconomic environment. Ingredion chairman and chief executive Jim Zallie said combining the "complementary portfolios creates a global leader in ingredient solutions," and targets around $130m of run-rate net cost synergies by the end of 2030.
At the Court Meeting on 28 July 2026, 98.64% of votes cast by value were in favour, matched at the General Meeting. Irrevocable undertakings already covered 17.1% of the shares, including 75 million (16.8%) held by Huber Equity Corporation, the former owner of CP Kelco. The scheme remains conditional on Material Antitrust Conditions in several jurisdictions and on court sanction, with the effective date expected in the second half of 2027.
What Tate & Lyle does
Tate & Lyle is no longer the sugar refiner of its origins; the sugar Business went in 2010 and the Primient corn-milling business was fully divested in 2024. Today it is a speciality food and beverage solutions company, supplying sweeteners, texturants, fibres and stabilisers that help customers cut sugar, calories and fat while improving mouthfeel and shelf life. The November 2024 Acquisition of CP Kelco added pectin and speciality gums, and the group now reports as one business across the Americas, EMEA and Asia Pacific. Revenue comes from selling ingredients and formulation expertise to food, beverage, dairy and bakery manufacturers, increasingly as bundled solutions, from 75 locations in 37 countries.
FY26 results: revenue down 3% and Earnings under pressure
The full-year results for the year ended 31 March 2026, published on 21 May 2026, help explain why the board chose cash certainty. Revenue was £2,006m, down 3% in constant currency, with the Americas at £995m (down 3%), EMEA at £636m (down 5%) and Asia Pacific at £375m (down 1%). Adjusted EBITDA fell 3% to £415m, a 20.7% margin. Adjusted profit before tax dropped 5% to £238m and adjusted Diluted Earnings per Share fell 16% in constant currency to 40.4 pence; statutory profit before tax was £131m and statutory diluted EPS from continuing operations 21.7 pence.
Free Cash Flow was £164m and net Debt stood at £939m, or 2.3 times EBITDA. The final dividend was held at 13.2 pence, giving a flat full-year payout of 19.8 pence. Integration of CP Kelco went better than the market did: £24m of cost synergies were delivered and the $50m run-rate target was hit a year early. Chief executive Nick Hampton said "our financial performance has been disappointing" and that the company was "acting with urgency to return the business to top-line growth." Pre-deal guidance for FY27 pointed to modest, second-half-weighted revenue growth and broadly flat EBITDA before a roughly $20m hit from delaying the bio-gums network consolidation into FY28.
What could drive the stock next
With the Shareholder vote secured, the calendar is dominated by regulatory milestones. Clearance under each of the Material Antitrust Conditions, and any remedies demanded by competition authorities, will determine whether and when the 595 pence is paid. Approvals arriving ahead of the guided second-half-2027 timetable would shorten the wait and lift the annualised return from any discount to the offer price.
The 6.8 pence interim dividend, part of the 615 pence total value, would normally be declared with half-year results in November, which will also show whether the expected Volume recovery has begun. A rival bidder could in theory emerge, though the level of shareholder support and Huber's irrevocable undertaking make that unlikely.
Risks investors should watch
The central risk is that the acquisition does not complete. Ingredion has reserved the right to invoke the antitrust conditions if remedies would be adverse "to a material extent" to its group, and the combination unites two large suppliers of texturants and sweeteners in several markets. A lapsed deal would leave the shares exposed to standalone fundamentals: falling revenue, a 16% drop in adjusted EPS and 2.3 times leverage, with the undisturbed price some 37% below the offer.
The long timeline itself is a cost: Capital is locked up for a year or more with the return capped at the Offer Price plus permitted dividends. A prolonged Offer Period can also weigh on customer wins and staff retention, softening the standalone business should the deal fail.
Outlook
Tate & Lyle (LSE:TATE) is not a sleeper stock in 2026; it is a merger-arbitrage situation with a fixed ceiling and a definable set of hurdles. The reward for holding is the difference between the Market Price and 615 pence including dividends, spread over a timetable stretching into late 2027. The risk is regulatory. Investors should track antitrust decisions in the key jurisdictions, any updated scheme timetable, the November half-year results and interim dividend, and Ingredion's own disclosures on approvals. Until then, the shares will trade on deal probability rather than on the ingredients business itself.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...